Last reviewed · How we verify
FluBlok
FluBlok is a recombinant influenza vaccine that stimulates immune response against influenza virus surface antigens.
FluBlok is a recombinant influenza vaccine that stimulates immune response against influenza virus surface antigens. Used for Prevention of influenza A and B in adults aged 18 years and older.
At a glance
| Generic name | FluBlok |
|---|---|
| Also known as | rHA Trivalent Recombinant Hemagglutinin Influenza Vaccine |
| Sponsor | The University of Hong Kong |
| Drug class | Recombinant protein vaccine |
| Target | Influenza hemagglutinin (HA) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
FluBlok uses recombinant hemagglutinin (HA) protein produced in insect cells (baculovirus expression system) rather than egg-based or cell culture methods. This allows rapid production of vaccine antigens matching circulating influenza strains, triggering both humoral and cellular immune responses to prevent influenza infection.
Approved indications
- Prevention of influenza A and B in adults aged 18 years and older
Common side effects
- Injection site pain
- Injection site erythema
- Injection site swelling
- Myalgia
- Headache
- Fatigue
Key clinical trials
- A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age (PHASE3)
- Open-Label Influenza Vaccine Evaluation (NA)
- The Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures (DRIVE III) Study (PHASE4)
- Randomized Influenza Vaccine Evaluation of Immune Response (PHASE4)
- Immunogenicity Trial of 3 Influenza Vaccines (PHASE3)
- Flublok or Fluzone With Advax-CpG55.2 or AF03 (PHASE1)
- Substudy 01 - Safety and Immunogenicity of One Monovalent Modified mRNA Vaccine Encoding Influenza Hemagglutinin With LNP, in Adult Participants Aged 18 to 49 Years and 60 Years and Above (PHASE1)
- Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) in Participants 9 Through 49 Years of Age. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FluBlok CI brief — competitive landscape report
- FluBlok updates RSS · CI watch RSS
- The University of Hong Kong portfolio CI